Niacinamide-mediated cytokine modulation

The phrase "Anti-inflammatory effect via niacinamide-mediated cytokine modulation" does not refer to a single molecular target or receptor. Instead, it describes a mechanistic pathway in which niacinamide (also known as nicotinamide or vitamin B3) exerts anti-inflammatory effects by modulating the production and activity of various inflammatory cytokines. This occurs primarily through suppression of the transcription factor NF-kB—leading to decreased expression of pro-inflammatory mediators like TNF-alpha and IL‑1β—and through inhibition of enzymes such as poly(ADP-ribose) polymerase 1 (PARP1), which are involved in immune cell signaling during inflammation and infection[2][3][4]. These actions are relevant for conditions characterized by excessive inflammation or "cytokine storms," including certain skin diseases and viral infections like COVID‑19. However, this entry is not a canonical therapeutic target such as a receptor or enzyme but rather describes an effect mediated by multiple molecular targets influenced by niacinamide. Therefore, it should not be considered a standard drug target entry; instead, specific molecules within this pathway—such as NF-kB or PARP1—would be appropriate canonical targets. If you require structured information on actual druggable targets within this mechanism—for example "NF-kappa-B" or "Poly(ADP-ribose) polymerase 1"—please specify.

Other names

NiacinamideNicotinamideVitamin B3 anti-inflammatory pathwayPARP-1 inhibition by nicotinamide

Suppression of NF-kB activation leading to reduced production of pro-inflammatory cytokines such as TNF-alpha and IL-1β[2] Inhibition of poly(ADP-ribose) polymerase 1 (PARP1), modulating immune response and potentially preventing cytokine storm[3]